An analysis of data from China suggests that around 15% of hospitalized COVID-19 patients had abnormal liver test results.
However, 42–67% of the patients in the Yale study had abnormal tests upon admission to the hospital, depending on which of two enzymes the tests measured.During hospitalization, these figures rose to 62% and 83%, respectively.The results appear in the journal Hepatology.Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.The researchers are unsure why the livers of COVID-19 patients in the U.S.
are more likely to have sustained damage, but underlying health differences between Chinese and U.S. populations may be responsible.“We can.